Navigation Links
TRIZCON2008 at Kent State, April 13-15
Date:2/19/2008

The Altshuller Institute for TRIZ Studies is pleased to announce TRIZCON2008, a conference that focuses on the Theory of Inventive Problem Solving (TRIZ). Celebrating its 10th anniversary, the largest international TRIZ conference in the world will be sponsored by and held at Kent State Universitys Student Center in Kent, Ohio, from April 13-15, 2008. This annual event provides an opportunity for both new and experienced users to get an in-depth introduction to TRIZ, selected advanced training in various TRIZ tools and concepts, and to meet with an international group of trainers and end-users.

A collage of concepts and tools that has captured the imagination of many Fortune 500 companies in the United States and abroad, TRIZ often is used in science and engineering circles to solve manufacturing problems and create new products. Companies that have used TRIZ concepts include BAE Systems, Brunswick-LifeFitness, Procter & Gamble, Ford, Boeing, Philips Semiconductor, LG Electronics, Delphi, Boston Scientific, Intel, Iwint-China, S.C. Johnson and Samsung among others.

Eight one-day workshops prior to and after the conference will be offered to introduce and enhance problem solving skills. Also on Saturday, April 12, a free pre-conference workshop will be offered for teachers (K-12 and college) who are interested in bringing TRIZ to the classroom. The first day of the conference, April 13, is dedicated to tutorials for beginners and advanced users of TRIZ, and a third track includes a live application of TRIZ on the Automotive X PRIZE competition that invites teams from around the world to focus on designing a viable, clean and super-efficient car that people want to buy.

During the rest of the conference, a symposium featuring more than 20 papers and case studies on TRIZ and related applications as well as a poster session will take place. In addition, the conference will offer five keynote speakers:

  • Ben Berry, Chief Informat
    '/>"/>

Contact: Melissa Edler
medler@kent.edu
330-672-8589
Kent State University
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Report Lists Key Policy Questions Facing State, National Health Reform
2. Researchers investigate links between prostate, cadmium, zinc
3. Intel Co-Founder Andrew S. Grove Dedicates Portion of His Estate, Up to $40 Million, to Michael J. Fox Foundation
4. Marin County Scandal and Elder Abuse Horror: Lawsuits Link Death Nurse, Bay Area lawyers, Doctor and Blind Eye by Local, State, and National Public Officials
5. Dr. Oliver Sacks, NYT Bestselling Author, to Inspire and Marc Black, Award-winning Musician, to Perform at National Aphasia Association Benefit on April 1, NYC
6. Sundance Channel to Premiere Documentary Autism Every Day on World Autism Awareness Day, April 2nd at 8:00pm et/pt
7. Parental Alienation Awareness Organization Begins Preparations for Parental Alienation Awareness Day - April 25th
8. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
9. Blue Cross and Blue Shield Companies to Host Second Annual National Walk @ Lunch Day(SM) on April 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5Ascension Orthopedics Hires Key Senior Executives 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6FDA Advisory Committee Votes in Favor of SAPHRIS 28R 29 28asenapine 29 for Acute Bipolar I Disorder and Acute Schizophrenia 4800 1FDA Advisory Committee Votes in Favor of SAPHRIS 28R 29 28asenapine 29 for Acute Bipolar I Disorder and Acute Schizophrenia 4800 2FDA Advisory Committee Votes in Favor of SAPHRIS 28R 29 28asenapine 29 for Acute Bipolar I Disorder and Acute Schizophrenia 4800 3FDA Advisory Committee Votes in Favor of SAPHRIS 28R 29 28asenapine 29 for Acute Bipolar I Disorder and Acute Schizophrenia 4800 4VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE 4799 1VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE 4799 2VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE 4799 3Americans Spend Billions on Alternative Medicine 53255 1Americans Spend Billions on Alternative Medicine 53255 2Americans Spend Billions on Alternative Medicine 53255 3
Other Medicine Technology:IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP) 2IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP) 3IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP) 4IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP) 5Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 2Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 3Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 4Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 5